*For medical professionals only

Prospective SOURCE STUDIES add strong evidence

FlaURA study confirmed the remarkable efficacy and good safety of osimtinib in the first-line treatment of EGFR mutation-positive advanced NSCLC, FLOURISH research further demonstrated the efficacy and safety of osimtinib first-line treatment in the real world in China, providing more comprehensive and more complete evidence of first-line treatment of osimtinib in patients with positive EGFR mutations in advanced NSCLC in China, and we believe that oshitinib as the first-line standard treatment of this population will benefit more Chinese patients
。
*Deadline2022-9-12Inscienter
Profile
Zhou Jianya Professor, Doctoral Supervisor, Chief Physician; Deputy Director of the Department of Respiratory Medicine, The First Affiliated Hospital of Zhejiang University School of Medicine (presided over the work); Director of Zhejiang Clinical Research Center for Respiratory Diseases; Director of the Chinese Society of Clinical Oncology (CSCO), member of the Special Committee on Non-small Cell Lung Cancer; Member of tobacco disease group of respiratory branch of Chinese Medical Association, member of medical ethics branch group; Member of Respiratory Branch of Zhejiang Medical Association; Member of the Lung Cancer Committee of Zhejiang Anti-Cancer Association, Standing Committee Member of the Tumor Marker Committee; Inspector of new drugs of the State Food and Drug Administration; Visiting Scholar, Sidney Kimmel Cancer Center, Johns Hopkins Hospital, USA; He has presided over 3 national natural science foundations, published more than 10 SCI papers by the first author, and participated in a number of international multi-center clinical trials
.

References:

[1] Hong Shaodong, Zhang Li.
New progress and prospect of targeted therapy for lung cancer[J].
Chinese Journal of Oncology, 2020,30(10):733-743.
[2] Soria JC, Ohe Y, Vansteenkiste J, et al.
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
N Engl J Med.
2018 Jan 11; 378(2):113-125.
[3] Reungwetwattana T, Nakagawa K, Cho BC, et al.
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol.
2018 Aug 28:JCO2018783118.
[4]S.
S.
Ramalingam, J.
E.
Gray, Y.
Ohe, et al.
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis.
Annals of Oncology (2019) 30 (suppl_5): v851-v934.
[5] Cheng Y, He Y, Li W, et al.
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Target Oncol.
2021 Mar; 16(2):165-176.
[6] Jianying Zhou, Jianya Zhou, Jing Zheng, et al.
Real-World Outcomes of First-Line Osimertinib for EGFR Mutated Advanced NSCLC Patients in China: Interim Analysis of FLOURISH Study.
2022ESMO 1123P.
* This article is for the sole purpose of providing scientific information to medical professionals and does not represent the views of this platform